Noxopharm Limited
7
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.9%
3 terminated/withdrawn out of 7 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
133%
4 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Role: lead
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Role: lead
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
Role: lead
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Role: lead
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
Role: lead
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Role: lead
A Study of Safety and Tolerability of NOX66 in Healthy Volunteers
Role: lead
All 7 trials loaded